Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment
Ketao Jin,Ze-Bei Lu,Jin-Yang Chen,Yuyao Liu,Huan-Rong Lan,Hai-Ying Dong,Fan Yang,Yuan-Yuan Zhao,Xiao-Yi Chen +8 more
TLDR
The advances in this area through the review of novel NP drug formulations developed over the last year are described, focusing specifically on lung, colon, cervical, and breast cancers, and the future of NPs as potential treatment options are discussed.Abstract:
Chemotherapy drugs are cytotoxic to tumor cells, but their lack of specificity leads to a range of side effects. The off-target effects of such drugs can be improved through the use of nanoparticles (NPs). Administered NPs show enhanced accumulation in tumor tissue near the blood vessels, enhancing both anticancer drug permeability and tumor retention. Several nanocarriers are now approved for clinical use in a range of cancer therapies, and many novel formulations are in the later stages of clinical trials. Here, we describe the advances in this area through the review of novel NP drug formulations developed over the last year. We focus specifically on lung, colon, cervical, and breast cancers and discuss the future of NPs as potential treatment options in these areas.read more
Citations
More filters
Journal ArticleDOI
Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy
TL;DR: This Review presents different nanocarriers, targeting, and functional moieties responsive to a variety of stimuli such as pH, enzyme, Temperature, redox stimulus and the problems and potential achievements in the field of SDDS.
Journal ArticleDOI
Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells
Monika Ruzycka-Ayoush,Patrycja Kowalik,Patrycja Kowalik,Agata Kowalczyk,Piotr Bujak,Anna M. Nowicka,Maria Wojewódzka,Marcin Kruszewski,Ireneusz P. Grudzinski +8 more
TL;DR: In this article, a targeted drug delivery (TDD) system based on Ag-In-Zn-S quantum dots (QDs) was developed for small cell lung cancer, which is characterized by a lack of specificity, resulting in severe adverse effects.
Journal ArticleDOI
Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer.
Sunil Kumar Dubey,Maithili Kali,Siddhanth Hejmady,Ranendra Narayan Saha,Amit Alexander,Prashant Kesharwani +5 more
TL;DR: In this article, the authors discuss the utilization of dendrimers for treating breast cancer and conquering the limitations of multidrug resistance, and discuss the use of nanocarriers for targeted delivery of drugs resulting in reduced side effects.
Journal ArticleDOI
DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges.
Fakhara Sabir,Mahira Zeeshan,Ushna Laraib,Mahmood Barani,Abbas Rahdar,Magali Cucchiarini,Sadanand Pandey +6 more
TL;DR: In this paper, the authors summarized the insights about various types of DNA nanostructures and stimuli responsive nanocarrier systems applications for diagnosis and treatment of cancer, and showed that the DNA-based and stimuli-responsive nano-carrier systems are perfect tools to overcome the problems existing in the cancer treatment including toxicity and compromised drug efficacy.
References
More filters
Journal ArticleDOI
Doxil®--the first FDA-approved nano-drug: lessons learned.
TL;DR: This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use and demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles.
Journal ArticleDOI
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Susan K. Hobbs,Wayne L. Monsky,Fan Yuan,W. G. Roberts,Linda G. Griffith,Vladimir P. Torchilin,Rakesh K. Jain +6 more
TL;DR: Delivery may be less efficient in cranial tumors than in subcutaneous tumors, delivery may be reduced during tumor regression induced by hormonal ablation, and permeability to a molecule is independent of pore cutoff size as long as the diameter of the molecule is much less than the pore diameter.
Journal ArticleDOI
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Daniel Bobo,Kye J. Robinson,Jiaul Islam,Jiaul Islam,Kristofer J. Thurecht,Simon R. Corrie,Simon R. Corrie +6 more
TL;DR: An up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process is provided, and there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials.
Journal Article
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
TL;DR: There are many potential barriers to the effective delivery of a drug in its active form to solid tumors, and small-molecule chemotherapeutic agents have a large volume of distribution on i.v. administration.
Journal ArticleDOI
Nanoparticles in the clinic: An update.
TL;DR: A 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic are provided.
Related Papers (5)
Possible role of nanocarriers in drug delivery against cervical cancer
Swati Gupta,Manish K. Gupta +1 more